"'真金白银'的税费优惠为我们研发新产品提供了动力，去年我们将税收优惠资金全部投入技术升级与 产品创新中，公司现在已进入'政策支持—企业发展—利税增长'的良性循环。"开封联昌药业有限公司 董事长宋恒志介绍。 税收一头连着国家，一头连着企业、百姓。为助力民营企业抢占发展制高点，开封税务部门积极开 展"问需解难"走访活动，结合企业所得税汇算清缴、电子税务局操作实务等发现的问题，为民营企 业"量身定制"税费优惠政策"大礼包"和税收辅导"小课堂"，帮助民营企业算清算细政策红利账。 下一步，开封税务部门将结合实际，找准税收服务民营企业发展战略定位，进一步贯彻执行深化税收改 革措施，为民营企业提供更加公平、透明、便利的税收环境，让民营经济创新源泉充分涌流、创造活力 充分迸发。（书童 刘沙） 坐落于开封市禹王台区的河南盛宏丰化工有限公司是一家集科研、生产制造及销售于一体的高新技术企 业，主要产品为甲醇钠甲醇溶液、甲醛溶液，是亚洲最大的液体甲醇钠生产企业。 成绩的取得离不开税务部门的扶持与帮助。在政策辅导上，禹王台区税务局定期举办培训，帮助企业准 确理解和运用最新政策。在办税服务方面，当地税务局工作人员通过"征纳互动"提供" ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6][8]. Core Views - The company experienced short-term pressure on performance, with a 10.16% year-on-year revenue growth to 1.32 billion yuan in 2024, but a 22.39% decline in net profit attributable to shareholders [3][4]. - The company is focusing on innovation and increasing R&D investment, which reached 118 million yuan in 2024, accounting for 8.95% of revenue, and is expected to drive long-term growth [5][6]. - The company has completed its capacity layout, enhancing multi-business synergy, with several projects operational by the end of 2024 [5]. Financial Performance Summary - In 2024, the company achieved revenue of 1.32 billion yuan, with a net profit of 63 million yuan, reflecting a decline in profitability due to increased competition and higher depreciation costs [3][4]. - For Q1 2025, the company reported revenue of 310 million yuan, a year-on-year increase of 8.16%, but a 24.73% decline in net profit [3][4]. - The company forecasts revenue growth rates of 10.2%, 8.4%, 8.9%, and 9.4% for the years 2024 to 2027, respectively [7][11]. Business Segment Performance - In 2024, the enzyme preparation segment generated 505 million yuan, the micro-ecology segment 193 million yuan, and the animal health products segment 308 million yuan, with respective gross margins of 63.69%, 37.29%, and 33.51% [4]. - For Q1 2025, the enzyme preparation segment achieved revenue of 120 million yuan, with a gross margin of 44.36% [4]. R&D and Innovation - The company has applied for 81 invention patents related to probiotics and has published 32 articles, enhancing its competitive strength in nutrition and health-related businesses [5][6]. - The integration of AI technology is expected to further strengthen the company's capabilities in product innovation and application design [5]. Future Earnings Forecast - The company is projected to achieve net profits of 74 million yuan in 2025, 81 million yuan in 2026, and 90 million yuan in 2027, with corresponding EPS of 0.29, 0.32, and 0.35 yuan [6][7].

本报讯 （记者刘钊）4月26日，青岛蔚蓝生物股份有限公司（以下简称"蔚蓝生物"）同时发布2024年年 度报告及2025年一季度报告。数据显示，2024年年度，公司实现营收13.21亿元，同比增长10.16%，收 入规模稳步增长，实现净利润6263.75万元。2025年一季度，公司营收达3.10亿元，同比增长8.16%。 蔚蓝生物主要从事酶制剂、微生态制剂以及动物保健品的研发、生产和销售。公司以"生物科技还原生 态世界"为宗旨，致力于为生物制造提供核心技术支持，为传统产业提供清洁节能技术，为食品安全提 供绿色解决方案，全程服务农业、食品、洗涤、健康、环保、生物催化等多个产业。公司坚持技术创新 战略，持续加大研发投入，致力于打造以技术创新和全球化驱动的工业生物平台。 2024年，公司研发投入1.18亿元，占营业收入的8.95%，同比增长6.81%，在行业中处于较高水平。公司 持续优化价值客户的服务方案与运营效率，强化主业竞争力，并在全球化布局上深化"一带一路"产业布 局，推动国际市场拓展。 据悉，酶制剂、微生态制剂等生物行业是我国战略性新兴产业，具备高效、安全、节能、环保等特点， 是我国建设资源节约型、环境友好型 ...